20.76 USD
+0.38 (+1.86%)
SIBN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. While SIBN seems to be doing ok healthwise, there are quite some concerns on its profitability. SIBN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SIBN has reported negative net income.
SIBN had a negative operating cash flow in the past year.
In the past 5 years SIBN always reported negative net income.
In the past 5 years SIBN always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -9.29%, SIBN is doing good in the industry, outperforming 61.96% of the companies in the same industry.
SIBN has a Return On Equity of -12.64%. This is in the better half of the industry: SIBN outperforms 66.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.29% | ||
| ROE | -12.64% | ||
| ROIC | N/A |
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 79.62%, SIBN belongs to the best of the industry, outperforming 91.85% of the companies in the same industry.
In the last couple of years the Gross Margin of SIBN has declined.
SIBN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
SIBN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SIBN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SIBN has more shares outstanding
The debt/assets ratio for SIBN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.27 indicates that SIBN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.27, SIBN belongs to the top of the industry, outperforming 84.78% of the companies in the same industry.
A Debt/Equity ratio of 0.21 indicates that SIBN is not too dependend on debt financing.
The Debt to Equity ratio of SIBN (0.21) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.27 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
A Current Ratio of 7.97 indicates that SIBN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.97, SIBN belongs to the best of the industry, outperforming 89.13% of the companies in the same industry.
SIBN has a Quick Ratio of 6.62. This indicates that SIBN is financially healthy and has no problem in meeting its short term obligations.
SIBN has a better Quick ratio (6.62) than 88.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.97 | ||
| Quick Ratio | 6.62 |
3. Growth
3.1 Past
SIBN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.57%, which is quite impressive.
Looking at the last year, SIBN shows a very strong growth in Revenue. The Revenue has grown by 23.27%.
Measured over the past years, SIBN shows a quite strong growth in Revenue. The Revenue has been growing by 19.96% on average per year.
EPS 1Y (TTM)44.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
Revenue 1Y (TTM)23.27%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%20.61%
3.2 Future
Based on estimates for the next years, SIBN will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.03% on average per year.
The Revenue is expected to grow by 16.30% on average over the next years. This is quite good.
EPS Next Y28.75%
EPS Next 2Y15.8%
EPS Next 3Y16.03%
EPS Next 5YN/A
Revenue Next Year19.76%
Revenue Next 2Y17.51%
Revenue Next 3Y16.64%
Revenue Next 5Y16.3%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
SIBN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIBN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SIBN's earnings are expected to grow with 16.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.8%
EPS Next 3Y16.03%
5. Dividend
5.1 Amount
No dividends for SIBN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:SIBN (12/22/2025, 12:21:52 PM)
20.76
+0.38 (+1.86%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners92.45%
Inst Owner Change1.17%
Ins Owners2.87%
Ins Owner Change-4.76%
Market Cap900.78M
Revenue(TTM)193.58M
Net Income(TTM)-21.75M
Analysts84
Price Target25.73 (23.94%)
Short Float %6.67%
Short Ratio4.76
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.24%
Min EPS beat(2)25.4%
Max EPS beat(2)35.08%
EPS beat(4)4
Avg EPS beat(4)30.34%
Min EPS beat(4)25.4%
Max EPS beat(4)35.08%
EPS beat(8)8
Avg EPS beat(8)24.69%
EPS beat(12)12
Avg EPS beat(12)24.73%
EPS beat(16)13
Avg EPS beat(16)17.22%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-0.9%
Max Revenue beat(2)2.22%
Revenue beat(4)3
Avg Revenue beat(4)1.07%
Min Revenue beat(4)-0.9%
Max Revenue beat(4)2.63%
Revenue beat(8)6
Avg Revenue beat(8)0.9%
Revenue beat(12)10
Avg Revenue beat(12)2.07%
Revenue beat(16)12
Avg Revenue beat(16)1.46%
PT rev (1m)1.34%
PT rev (3m)0.89%
EPS NQ rev (1m)-0.91%
EPS NQ rev (3m)6.47%
EPS NY rev (1m)11.43%
EPS NY rev (3m)10.94%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)0.83%
Revenue NY rev (1m)1.25%
Revenue NY rev (3m)1.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.65 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.23 | ||
| P/tB | 5.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.5
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS4.46
BVpS3.97
TBVpS3.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.29% | ||
| ROE | -12.64% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 79.62% | ||
| FCFM | N/A |
ROA(3y)-23.71%
ROA(5y)-24.08%
ROE(3y)-35.49%
ROE(5y)-34.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.65%
GM growth 5Y-2.54%
F-Score5
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 175.72% | ||
| Cap/Sales | 4.85% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.97 | ||
| Quick Ratio | 6.62 | ||
| Altman-Z | 7.27 |
F-Score5
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)219.68%
Cap/Depr(5y)238.27%
Cap/Sales(3y)6.94%
Cap/Sales(5y)6.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.25%
EPS Next Y28.75%
EPS Next 2Y15.8%
EPS Next 3Y16.03%
EPS Next 5YN/A
Revenue 1Y (TTM)23.27%
Revenue growth 3Y22.84%
Revenue growth 5Y19.96%
Sales Q2Q%20.61%
Revenue Next Year19.76%
Revenue Next 2Y17.51%
Revenue Next 3Y16.64%
Revenue Next 5Y16.3%
EBIT growth 1Y39.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year116.78%
EBIT Next 3Y36.48%
EBIT Next 5Y31.83%
FCF growth 1Y66.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y94.72%
OCF growth 3YN/A
OCF growth 5YN/A
SI-BONE INC / SIBN FAQ
What is the ChartMill fundamental rating of SI-BONE INC (SIBN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SIBN.
What is the valuation status of SI-BONE INC (SIBN) stock?
ChartMill assigns a valuation rating of 0 / 10 to SI-BONE INC (SIBN). This can be considered as Overvalued.
How profitable is SI-BONE INC (SIBN) stock?
SI-BONE INC (SIBN) has a profitability rating of 2 / 10.
What is the expected EPS growth for SI-BONE INC (SIBN) stock?
The Earnings per Share (EPS) of SI-BONE INC (SIBN) is expected to grow by 28.75% in the next year.